Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 14/20 | 0.94 |
| ▸ | CNR2 | P34972 | 13/20 | 0.94 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30609587 | 0.97 | CNR1 (1.00) | CNR1CNR2HTR3AKDM4E | |
| SCHEMBL29275142 | 0.97 | CNR1 (1.00) | CNR1CNR2HTR3AKDM4E | |
| SCHEMBL13691279 | 0.92 | CNR1 (0.83) | CNR1CNR2HTR3AKDM4E | |
| SCHEMBL25366701 | 0.90 | CNR1 (0.80) | CNR1CNR2HTR3AKDM4E | |
| SCHEMBL30353000 | 0.90 | CNR1 (0.80) | CNR1CNR2HTR3AKDM4E | |
| SCHEMBL4054847 | 0.89 | CNR1 (0.78) | CNR1CNR2HTR3AKDM4E | |
| SCHEMBL29275146 | 0.88 | CNR1 (0.76) | CNR1CNR2 | |
| SCHEMBL17613434 | 0.88 | CNR1 (0.80) | CNR1CNR2HTR3AKDM4E | |
| SCHEMBL13691142 | 0.88 | CNR1 (0.80) | CNR1CNR2HTR3AKDM4E | |
| SCHEMBL4050795 | 0.88 | CNR1 (0.80) | CNR1CNR2HTR3AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-3664795-B1 | CANNABIS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN AND INFLAMMATION RELATED WITH DENTAL PULP AND BONE REGENERATION RELATED TO DENTAL JAW BONE DEFECTS | CANNIBITE BVBA (BE) | 2024-06-19 | — | — | EP | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| CN-117805259-A | Method for rapidly analyzing 87 synthetic cannabinoids and metabolites thereof in urine after enzymolysis | 司法鉴定科学研究院 | 2024-04-02 | — | — | CN | claimed |
| CN-117110457-A | Analysis method for screening 50 new pollutants in sewage by micro-volume direct sample injection technology | 司法鉴定科学研究院 | 2023-11-24 | — | — | CN | claimed |
| CN-113419018-B | Pretreatment method of incense sample and method for detecting various cannabinoids in incense smoke | 福州海关技术中心 | 2022-06-17 | — | — | CN | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4646477-A2 | METHODS AND COMPOSITIONS FOR DISPLAYING PEPTIDE LIBRARIES | Board of Regents, The University of Texas System (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250241933-A1 | METHODS OF TREATING SLEEP APNEA WITH A COMBINATION OF A CANNABINOID AND A CARBONIC ANHYDRASE INHIBITOR | APNIMED, INC. (DELAWARE) | 2025-07-31 | — | — | US | disclosed |
| EP-4543431-A1 | METHODS OF TREATING SLEEP APNEA WITH A COMBINATION OF A CANNABINOID AND A CARBONIC ANHYDRASE INHIBITOR | APNIMED, INC. (DELAWARE) (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119403548-A | Method of treating sleep apnea with a combination of cannabinoid and carbonic anhydrase inhibitors | 爱普宁公司(特拉华) | 2025-02-07 | — | — | CN | disclosed |
| WO-2022221613-A1 | COMBINATION OF A NOREPINEPHRINE REUPTAKE INHIBITOR AND A CANNABINOID FOR USE IN TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) (US) | 2022-10-20 | — | — | WO | disclosed |
| CN-113419018-B | Pretreatment method of incense sample and method for detecting various cannabinoids in incense smoke | 福州海关技术中心 | 2022-06-17 | — | — | CN | disclosed |
| EP-2989452-B1 | NUCLEAR MAGNETIC RESONANCE BASED SYNTHETIC INDOLE AND INDAZOLE CANNABINOID DETECTION, IDENTIFICATION, AND QUANTIFICATION | HOFSTRA UNIV (US) | 2021-09-29 | — | — | EP | disclosed |
| US-11085891-B2 | Nuclear magnetic resonance implemented synthetic indole and indazole cannabinoid detection, identification, and quantification | HOFSTRA UNIVERSITY (US) | 2021-08-10 | — | — | US | disclosed |
| US-20160084779-A1 | NUCLEAR MAGNETIC RESONANCE IMPLEMENTED SYNTHETIC INDOLE AND INDAZOLE CANNABINOID DETECTION, IDENTIFICATION, AND QUANTIFICATION | HOFSTRA UNIVERSITY (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160084779-A1 | NUCLEAR MAGNETIC RESONANCE IMPLEMENTED SYNTHETIC INDOLE AND INDAZOLE CANNABINOID DETECTION, IDENTIFICATION, AND QUANTIFICATION | HOFSTRA UNIVERSITY (US) | 2016-03-24 | — | — | US | disclosed |
| WO-2014176542-A1 | NUCLEAR MAGNETIC RESONANCE IMPLEMANTED SYNTHETIC INDOLE AND INDAZOLE CANNABINOID DENTECTION, IDENTIFICATION, AND QUANTIFICATION | HOFSTRA UNIVERSITY (US) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | CNR1 221/4885CNR2 204/4885HTR3A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.